1.04
price up icon8.33%   0.08
after-market Handel nachbörslich: .85 -0.19 -18.27%
loading

Silexion Therapeutics Corp Aktie (SLXN) Neueste Nachrichten

pulisher
May 30, 2025

Silexion’s SIL-204 shows promise in pancreatic, colorectal and lung cancer cell lines - BioWorld MedTech

May 30, 2025
pulisher
May 29, 2025

Silexion Therapeutics Corp (SLXN)’s RNAi Therapy Blocks 90% of Colorectal Tumors - Yahoo Finance

May 29, 2025
pulisher
May 29, 2025

Silexion reports breakthrough in KRAS-driven cancer therapy By Investing.com - Investing.com Nigeria

May 29, 2025
pulisher
May 29, 2025

Silexion reports breakthrough in KRAS-driven cancer therapy - Investing.com Australia

May 29, 2025
pulisher
May 29, 2025

Silexion Therapeutics Announces Groundbreaking Preclinical Results: SIL204 Shows Strong Efficacy in Pancreatic, Colorectal, and Lung Cancers - The Manila Times

May 29, 2025
pulisher
May 29, 2025

Silexion Therapeutics Announces Groundbreaking Preclinical - GlobeNewswire

May 29, 2025
pulisher
May 29, 2025

Revolutionary Cancer Drug Shows 90% Inhibition Rate Against Pancreatic, Lung, and Colorectal Cancers in New Study - Stock Titan

May 29, 2025
pulisher
May 26, 2025

Reviewing Silexion Therapeutics (NASDAQ:SLXN) & BioNTech (NASDAQ:BNTX) - Defense World

May 26, 2025
pulisher
May 23, 2025

Silexion Therapeutics Receives Nasdaq Delisting Notice - TipRanks

May 23, 2025
pulisher
May 22, 2025

PESG Research Report: A Review of Silexion Therapeutics' Innovative KRAS-Driven Cancer Treatment - TradingView

May 22, 2025
pulisher
May 21, 2025

Silexion's SIL204 Completes Key Preclinical Studies In KRAS-Mutant Cancers - Nasdaq

May 21, 2025
pulisher
May 21, 2025

Silexion Therapeutics Completes Key Preclinical Studies Exploring Sil204's Potential Impact on Colorectal and Lung Cancer - marketscreener.com

May 21, 2025
pulisher
May 21, 2025

Silexion Completes Key Preclinical Studies for SIL204 - TipRanks

May 21, 2025
pulisher
May 21, 2025

Silexion Therapeutics Completes Key Preclinical Studies Exploring SIL204's Potential Impact on Colorectal and Lung Cancer - The Manila Times

May 21, 2025
pulisher
May 21, 2025

Silexion Therapeutics Completes Key Preclinical Studies - GlobeNewswire

May 21, 2025
pulisher
May 21, 2025

Major Cancer Treatment Advance: Silexion's RNAi Drug Shows Promise Against 3 Deadly Cancers in $30B Market - Stock Titan

May 21, 2025
pulisher
May 13, 2025

Form 424B3 Silexion Therapeutics - StreetInsider

May 13, 2025
pulisher
May 13, 2025

Silexion Therapeutics Reports First Quarter 2025 Financial Results And Provides Business Update - marketscreener.com

May 13, 2025
pulisher
May 13, 2025

Silexion Therapeutics Reports Q1 2025 Financial Results and Key Developments in RNAi Cancer Therapy - Nasdaq

May 13, 2025
pulisher
May 13, 2025

Silexion Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update - GlobeNewswire

May 13, 2025
pulisher
May 02, 2025

SLXNSilexion Therapeutics Corp Latest Stock News & Market Updates - Stock Titan

May 02, 2025
pulisher
Apr 25, 2025

Is Silexion Therapeutics Corp (SLXN) positioned for future growth? - Sete News

Apr 25, 2025
pulisher
Apr 23, 2025

Silexion Therapeutics Partners with Catalent to Advance Revolutionary KRAS-Targeting Cancer Therapy - citybuzz -

Apr 23, 2025
pulisher
Apr 23, 2025

Silexion Therapeutics partners with Catalent for cancer drug development By Investing.com - Investing.com South Africa

Apr 23, 2025
pulisher
Apr 23, 2025

SLXN’s price-to-sales ratio: Is it a good investment opportunity? - uspostnews.com

Apr 23, 2025
pulisher
Apr 23, 2025

Silexion Partners With Catalent To Advance SIL204 SiRNA Therapy For KRAS-Driven Cancers - Nasdaq

Apr 23, 2025
pulisher
Apr 23, 2025

Silexion Therapeutics Partners with Catalent for SIL204 Development - TipRanks

Apr 23, 2025
pulisher
Apr 23, 2025

Silexion Therapeutics partners with Catalent for cancer drug development - Investing.com Australia

Apr 23, 2025
pulisher
Apr 23, 2025

Silexion Therapeutics enters collaboration with Catalent - TipRanks

Apr 23, 2025
pulisher
Apr 23, 2025

Silexion Therapeutics Announces Collaboration with Global Therapeutics Leader Catalent on Advanced siRNA Formulation Development & Clinical Manufacturing Activities - The Manila Times

Apr 23, 2025
pulisher
Apr 23, 2025

Silexion Therapeutics Enters Strategic Collaboration with Catalent to Advance SIL204 Development for KRAS-Driven Cancers - Nasdaq

Apr 23, 2025
pulisher
Apr 23, 2025

Silexion Therapeutics Announces Collaboration with Global - GlobeNewswire

Apr 23, 2025
pulisher
Apr 23, 2025

Major Breakthrough: Silexion's Multi-KRAS Cancer Drug Enters Manufacturing Phase with Industry Giant Catalent - Stock Titan

Apr 23, 2025
pulisher
Apr 05, 2025

Titan Pharmaceuticals (NASDAQ:TTNP) and Silexion Therapeutics (NASDAQ:SLXN) Head to Head Review - Defense World

Apr 05, 2025
pulisher
Mar 31, 2025

Silexion plans dual-route strategy for SIL-204 for KRAS-driven pancreatic cancer - BioWorld MedTech

Mar 31, 2025
pulisher
Mar 29, 2025

Buy Rating for Silexion Therapeutics Driven by Promising SIL-204 Developments and Market Expansion - TipRanks

Mar 29, 2025
pulisher
Mar 28, 2025

Silexion advances dual-route strategy for KRAS cancer therapy By Investing.com - Investing.com South Africa

Mar 28, 2025
pulisher
Mar 28, 2025

Silexion Therapeutics Unveils Innovative Expanded Development Plan for SIL204 Based on Recent Groundbreaking Preclinical Data - markets.businessinsider.com

Mar 28, 2025
pulisher
Mar 28, 2025

Silexion Therapeutics Unveils Innovative Expanded - GlobeNewswire

Mar 28, 2025
pulisher
Mar 28, 2025

Silexion Therapeutics announces expanded development plan for SIL204 - TipRanks

Mar 28, 2025
pulisher
Mar 28, 2025

Silexion Therapeutics Expands SIL204 Development Plan - TipRanks

Mar 28, 2025
pulisher
Mar 28, 2025

Silexion advances dual-route strategy for KRAS cancer therapy - Investing.com

Mar 28, 2025
pulisher
Mar 28, 2025

Silexion Therapeutics Corp Unveils Expanded Development Plan For Sil204 - MarketScreener

Mar 28, 2025
pulisher
Mar 28, 2025

Game-Changing Cancer Treatment: Silexion's New Dual-Action Drug Targets Both Primary Tumors and Metastases - Stock Titan

Mar 28, 2025
pulisher
Mar 23, 2025

Maxim Group Cuts Silexion Therapeutics (NASDAQ:SLXN) Price Target to $5.00 - Defense World

Mar 23, 2025
pulisher
Mar 21, 2025

Silexion Therapeutics price target lowered to $5 from $9 at Maxim - MSN

Mar 21, 2025
pulisher
Mar 21, 2025

Silexion announces completion of expanded development plan for SIL204 - TipRanks

Mar 21, 2025
pulisher
Mar 21, 2025

Silexion Therapeutics Corp. Announces Expanded Development Plan for SIL204 at NeauxCancer 2025 Conference - Nasdaq

Mar 21, 2025
pulisher
Mar 21, 2025

Silexion Therapeutics Announces Completion of Innovative Expanded Development Plan for SIL204 which will be unveiled at the 2025 NeauxCancer Conference - GlobeNewswire

Mar 21, 2025
pulisher
Mar 21, 2025

Revolutionary KRAS Cancer Treatment: Silexion Expands Development Strategy for SIL204 - StockTitan

Mar 21, 2025
pulisher
Mar 18, 2025

Silexion Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update - The Manila Times

Mar 18, 2025
pulisher
Mar 18, 2025

Silexion Therapeutics Corp. Reports 2024 Financial Results and Progress on SIL204 for KRAS-Driven Cancers - Nasdaq

Mar 18, 2025
pulisher
Mar 18, 2025

Silexion Therapeutics Corp SEC 10-K Report - TradingView

Mar 18, 2025
pulisher
Mar 17, 2025

Revolutionary Cancer Drug SIL204 Tackles Both Primary Tumors and Metastasis with 80% Success Rate - StockTitan

Mar 17, 2025
$1.08
price up icon 1.89%
$30.14
price down icon 3.74%
$573.26
price down icon 1.32%
$304.56
price up icon 3.98%
$4.50
price down icon 3.02%
$490.28
price down icon 19.01%
Kapitalisierung:     |  Volumen (24h):